Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by Stocktreeon Oct 17, 2016 6:11pm
126 Views
Post# 25353284

RE:RE:RE:Italian sensation Dr.Claudio Ronco...

RE:RE:RE:Italian sensation Dr.Claudio Ronco...
On not hard evidence (e.g. literature), we can only guess.

We have "vague" statements that lead us to believe we would be presented with great results.

We were fed several bits of information 30% to 50% CM and 62% non-consent M.

If we were somewhere around 50% CM mid trial, there is no way we could have 45% for the last 176 patients.

Of course, the 30% and 50% don't compute for me at patient 371. But it seems those numbers were never corrected.

270 patients before protocol change at CM 30% would be 81 patients dying.
371 = randomized patients, 50% CM on average, would be 185 patients dying
101 patients randomized since protocol change: 185-81=104/101 patients dying

So more patients dying that the total new patients randomized. I would gladly accept if someone would correct me, but for now, I see two numbers, and maybe both are incorrect. Ronco was incorrect, unless proven by a text document, that this was an abdominal trial. Their endpoint count in their last NR was wrong. You say they were wrong on their last 180 patients.

So how can we count on them about vague secondary end points, or a very fine but not qualified 18%... we can hope, we can bet, but considering how I was confident prior to results, I can't say I will believe anything coming from them, other than "we are sorry, we mislead you..."
Bullboard Posts